Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY EBITDA Margin
EBITDA as a percentage of revenue.
Eli Lilly and CompanyNYSE: LLY
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 56.5%
EBITDA Margin was 56.5% in Q2 FY2026, up 8.3 pp from a year earlier. On a trailing-twelve-month basis it was 54.4%, up 14.4 pp year over year. Over 3 fiscal years it widened by 18.3 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 18 analysts of 45.3% for the fiscal year ending Dec 2026, down from 48.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 56.5%+4.6 pp QoQ
- Last fiscal yearDec 2025
- 48.6%+6.9 pp YoY
- LTMJun 2026
- 54.4%+14.4 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.3 pp | -14.2 pp | -22.5 pp |
| 1 year | +6.9 pp | -3.4 pp | -10.2 pp |
| 3 years | +18.3 pp | +7.9 pp | -10.4 pp |
| 5 years | +12.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 48.6%
- Year-over-year change
- +6.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 48.6% | +6.9pp |
| FY2024 | 2024-12-31 | 41.8% | +16.6pp |
| FY2023 | 2023-12-31 | 25.1% | -5.2pp |
| FY2022 | 2022-12-31 | 30.3% | +1.9pp |
| FY2021 | 2021-12-31 | 28.4% | — |
EBITDA Margin vs competitors
How LLY compares with its peers on the latest reported figures
- LLY's LTM Jun 2026 EBITDA Margin of 54.4% is the 2nd highest of the 10 companies compared; the peer median is 34.4%.
- Its year-over-year change of +14.4 pp is the 2nd highest of 10, against a peer median of -0.5 pp.
- Over three fiscal years its change of +18.3 pp compares with a peer median of +7.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 54.9% | -0.5 pp | +7.3 pp | |
| LTM Jun 2026 | 54.4% | +14.4 pp | +18.3 pp | |
| LTM Jun 2026 | 46.2% | +0.7 pp | -0.2 pp | |
| LTM Jun 2026 | 40.0% | -1.1 pp | +8.2 pp | |
| LTM Sep 2026 | 36.6% | +15.1 pp | -12.8 pp | |
| LTM Sep 2026 | 34.4% | +3.4 pp | +13.3 pp | |
| LTM Sep 2026 | 31.0% | -11.9 pp | +10.3 pp | |
| LTM Jun 2026 | 30.2% | +0.6 pp | -6.6 pp | |
| LTM Jun 2026 | 21.2% | -10.4 pp | -13.7 pp | |
| LTM Jun 2026 | 21.0% | -18.3 pp | +7.6 pp | |
| Peer median (excluding LLY) | 34.4% | -0.5 pp | +7.3 pp | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B |
| Cost of Revenue | 7.31B | 6.63B | 7.08B | 8.42B | 11.05B |
| Gross Profit | 21.01B | 21.91B | 27.04B | 36.63B | 54.13B |
| Gross Margin | 74.2% | 76.8% | 79.2% | 81.3% | 83.0% |
| Research & Development | 6.93B | 7.19B | 9.31B | 10.99B | 13.34B |
| Selling, General & Admin | 6.14B | 6.07B | 6.94B | 8.59B | 11.09B |
| Operating Expenses | 13.07B | 13.26B | 16.25B | 19.59B | 24.43B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| EBITDA | 8.04B | 8.66B | 8.57B | 18.81B | 31.69B |
| EBITDA Margin | 28.4% | 30.3% | 25.1% | 41.8% | 48.6% |
| Operating Income | 7.93B | 8.65B | 10.79B | 17.04B | 29.7B |
| Operating Margin | 28.0% | 30.3% | 31.6% | 37.8% | 45.6% |
| Interest Income | 25.4M | 62.8M | 173.6M | 175.2M | 153.3M |
| Interest Expense | 339.8M | 331.6M | 485.9M | 780.6M | 795.3M |
| Other Income / Expenses | (1.78B) | (1.85B) | (4.23B) | (4.36B) | (3.97B) |
| Income Before Tax | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B |
| Pre-Tax Margin | 21.7% | 23.8% | 19.2% | 28.2% | 39.5% |
| Income Tax Expense | 573.8M | 561.6M | 1.31B | 2.09B | 5.09B |
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Net Margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| EPS (Basic) | 5.85 | 6.57 | 5.83 | 11.76 | 23.07 |
| EPS (Diluted) | 5.85 | 6.57 | 5.80 | 11.71 | 22.95 |
| Weighted Avg Shares | 953.65M | 950.18M | 899.38M | 900.61M | 898M |
| Weighted Avg Shares (Diluted) | 953.65M | 950.18M | 903.28M | 904.06M | 898M |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.